BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22750733)

  • 1. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.
    Sakai S; Nakaseko C; Takeuchi M; Ohwada C; Shimizu N; Tsukamoto S; Kawaguchi T; Jiang M; Sato Y; Ebinuma H; Yokote K; Iwama A; Fukamachi I; Schneider WJ; Saito Y; Bujo H
    Clin Chim Acta; 2012 Oct; 413(19-20):1542-8. PubMed ID: 22750733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel biomarker for pathological immature cells--soluble form of LR11].
    Bujo H
    Rinsho Byori; 2012 May; 60(5):469-76. PubMed ID: 22774576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased circulating soluble LR11 in patients with acute coronary syndrome.
    Ogita M; Miyauchi K; Dohi T; Tsuboi S; Miyazaki T; Yokoyama T; Yokoyama K; Shimada K; Kurata T; Jiang M; Bujo H; Daida H
    Clin Chim Acta; 2013 Jan; 415():191-4. PubMed ID: 23127357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
    Fujimura K; Ebinuma H; Fukamachi I; Ohwada C; Kawaguchi T; Shimizu N; Takeuchi M; Sakaida E; Jiang M; Nakaseko C; Bujo H
    Clin Chim Acta; 2014 Mar; 430():48-54. PubMed ID: 24394293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow.
    Shimizu N; Nakaseko C; Jiang M; Nishii K; Yokote K; Iseki T; Higashi M; Tamaru J; Schneider WJ; Bujo H
    Ann Hematol; 2014 Jul; 93(7):1111-22. PubMed ID: 24577511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LR11/SorLA links triglyceride-rich lipoproteins to risk of developing cardiovascular disease in FH patients.
    Vongpromek R; Bujo H; Hoekstra M; Schneider WJ; van der Zee L; Schinkel AF; Korporaal SJ; Dik WA; Ebinuma H; Jiang M; Verhoeven AJ; Sijbrands EJ; Mulder MT
    Atherosclerosis; 2015 Dec; 243(2):429-37. PubMed ID: 26520897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating soluble form of LR11, a regulator of smooth muscle cell migration, is a novel marker for intima-media thickness of carotid arteries in type 2 diabetes.
    Jin W; Jiang M; Han X; Han X; Murano T; Hiruta N; Ebinuma H; Piao L; Schneider WJ; Bujo H
    Clin Chim Acta; 2016 Jun; 457():137-41. PubMed ID: 27095609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble form of LR11 is highly increased in the vitreous fluids of patients with idiopathic epiretinal membrane.
    Hashimoto R; Jiang M; Shiba T; Hiruta N; Takahashi M; Higashi M; Hori Y; Bujo H; Maeno T
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):885-891. PubMed ID: 28102455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced circulating soluble LR11 in patients with coronary organic stenosis.
    Takahashi M; Bujo H; Jiang M; Noike H; Saito Y; Shirai K
    Atherosclerosis; 2010 Jun; 210(2):581-4. PubMed ID: 20047743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells.
    Nishii K; Nakaseko C; Jiang M; Shimizu N; Takeuchi M; Schneider WJ; Bujo H
    J Biol Chem; 2013 Apr; 288(17):11877-86. PubMed ID: 23486467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of circulating soluble LR11 on long-term clinical outcomes in patients with coronary artery disease.
    Ogita M; Miyauchi K; Kasai T; Tsuboi S; Wada H; Naito R; Konishi H; Dohi T; Tamura H; Okazaki S; Yanagisawa N; Shimada K; Suwa S; Jiang M; Bujo H; Daida H
    Atherosclerosis; 2016 Jan; 244():216-21. PubMed ID: 26687467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
    Sugita Y; Ohwada C; Kawaguchi T; Muto T; Tsukamoto S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Shimizu N; Tanaka H; Abe D; Fukazawa M; Sugawara T; Aotsuka N; Nishiwaki K; Shono K; Ebinuma H; Fujimura K; Bujo H; Yokote K; Nakaseko C
    Clin Chim Acta; 2016 Dec; 463():47-52. PubMed ID: 27725222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of circulating soluble LR11, a regulator of smooth muscle cell migration, are highly associated with atherosclerotic plaques in patients with carotid artery stenosis.
    Harada M; Jiang M; Terai K; Ebinuma H; Hiruta N; Schneider WJ; Sugo N; Nagao T; Bujo H
    Clin Chim Acta; 2019 Mar; 490():69-76. PubMed ID: 30550937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury.
    Ogita M; Miyauchi K; Jiang M; Kasai T; Tsuboi S; Naito R; Konishi H; Dohi T; Yokoyama T; Okazaki S; Shimada K; Bujo H; Daida H
    Atherosclerosis; 2014 Nov; 237(1):374-8. PubMed ID: 25443876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
    Dincaslan HU; Yavuz G; Unal E; Tacyildiz N; Ikinciogullari A; Dogu F; Guloglu D; Yuksek N; Ertem U
    Pediatr Hematol Oncol; 2010 Oct; 27(7):503-16. PubMed ID: 20677920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes.
    Tsukamoto S; Takeuchi M; Kawaguchi T; Togasaki E; Yamazaki A; Sugita Y; Muto T; Sakai S; Takeda Y; Ohwada C; Sakaida E; Shimizu N; Nishii K; Jiang M; Yokote K; Bujo H; Nakaseko C
    Exp Mol Med; 2014 Apr; 46(4):e89. PubMed ID: 24699135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease.
    Watanabe K; Suzuki H; Jiang M; Haniu H; Numano F; Hoshina S; Saitoh A; Uchiyama M; Bujo H
    Atherosclerosis; 2016 Mar; 246():94-7. PubMed ID: 26761773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of soluble LR11/SorLA are highly increased in the bile of patients with biliary tract and pancreatic cancers.
    Terai K; Jiang M; Tokuyama W; Murano T; Takada N; Fujimura K; Ebinuma H; Kishimoto T; Hiruta N; Schneider WJ; Bujo H
    Clin Chim Acta; 2016 Jun; 457():130-6. PubMed ID: 27079357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis.
    Matsuo M; Ebinuma H; Fukamachi I; Jiang M; Bujo H; Saito Y
    Clin Chem; 2009 Oct; 55(10):1801-8. PubMed ID: 19661140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia].
    Aulbert E; Fromm H; Hornemann H
    Med Klin (Munich); 1991 Jun; 86(6):297-304. PubMed ID: 1886510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.